Medicortex Finland Oy Announces Issuance of a Patent in Israel
Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the State of Israel Patent Office has issued a patent covering company’s new chemical compounds.
“We are extremely pleased with the development of the patent portfolio. This new issuance continues to expand the intellectual property portfolio covering methods of use for certain biomarker for the detection of concussion and associated therapy. The issuance of this patent is another step in the development of a robust patent portfolio relating to new strategy to help identify and treat mild TBI,” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid kit will satisfy the urgent need to improve the detection of brain injury in mild cases especially – which are potentially morbid but admittedly difficult to diagnose with the contemporary means. The issued patent covers new chemical entities which will serve for Medicortex’ other main program, the development of drug candidates for mitigating and preventing the harmful biochemical reaction cascades causing secondary brain injury following the primary trauma. Israel is the third issuance in the family of the patent in which relative national patents were previously granted in the USA and in Finland.
Medicortex’ patent portfolio encompasses the biomarkers diagnostics and the drug candidates developed by the company. The comprehensive patent coverage secures exclusivity to develop the products and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. The drug development program will be fully activated once the diagnostic kit development gets advanced. Medicortex was established by an Israeli neurobiologists Adrian Harel (PhD, MBA) in 2014, and the company is based in Turku, Finland.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, patent
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005218/en/
Contact information
Contacts
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Offers Students Free Access to Software for Continued Education Through Coronavirus Closures30.3.2020 16:29:00 EEST | Press release
Esri, the global leader in location intelligence, today announced that it will provide free access to its ArcGIS platform and learning resources through the Learn.ArcGIS.com website to support college and university students who no longer have access to campus computer labs during the COVID-19 outbreak. Students will receive access to ArcGIS Online and over 20 apps including ArcGIS Pro, along with a library of lessons to continue their learning and complete courses. Access is available globally to students ages 18 and over. Learn ArcGIS promotes learning by doing through guided lessons based on real-world problems in industries such as urban planning and disaster response, and new lessons on public health have just been added. Learn ArcGIS lessons cover both beginner and advanced topics and are available in seven languages. “We believe education creates opportunities for people of all ages, while building communities and advancing our knowledge for a better world,” said Jack Dangermond
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan30.3.2020 15:00:00 EEST | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma and related lymphomas. In January 2017, Daiichi Sankyo received exclusive development, manufacturing and commercialization rights for axicabtagene ciloleucel in Japan from California-based Kite, a Gilead Company. The Japan NDA submission is based on previous pivotal trial data conducted globally by Kite for axicabtagene ciloleucel in addition to results from a phase 2 bridging study conducted by Daiichi Sankyo in Japan. Both trials included patients with four aggressive types of relapsed/refractory B-cell lymphomas including diffuse large B cell lymphoma (DLBCL); primary mediastinal B-cell lymphoma (PMBCL); transformed follicular lymphoma (TF
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform30.3.2020 15:00:00 EEST | Press release
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates. In particular, Aptoru
HCL Technologies COVID-19 Status Update30.3.2020 11:40:00 EEST | Press release
HCL Technologies Ltd (HCL) has been monitoring the Covid-19 outbreak since late January and had invoked its Business Continuity Plan and Risk Management Framework quite early to minimize the impact on its employees and clients. The situation arising out of this outbreak and its rapid spread across the world is unprecedented and is extremely dynamic. The economic impact is visible with varying degrees of intensity across multiple countries where we operate. HCL has had a well-defined and structured pandemic policy in place which is resilient, pragmatic and accords paramount importance to employee safety & health and client commitments. We are actively engaged with our clients and have executed the client-specific and HCL internal operations-centric Business Continuity Plan that ensures continuity in delivering to our client and employee commitments. HCL is constantly reviewing the situation at hand with utmost priority and fully complying with all government advisories and recommendatio
GSMA Report Highlights That Mobile Money Accounts Now Exceed One Billion Worldwide30.3.2020 11:00:00 EEST | Press release
The GSMA today unveiled the annual ‘State of the Industry Report on Mobile Money’, offering a view of the mobile money landscape and highlighting the impact that greater financial inclusion has on lives, economies and innovation, especially in emerging markets. This year’s report looks at what one billion registered accounts means for the mobile money industry, mobile money users and the future of the mobile money ecosystem. It provides a comprehensive picture of adoption and usage around the globe. Significantly, the report highlights that 2019 marked a major milestone for the mobile money industry, with over one billion registered accounts and close to two billion dollars in daily transactions. For the first time, digital transactions represented the majority, 57 per cent, of mobile money interactions. The industry is witnessing increasing user trust and relevance. With 290 live services in 95 countries and 372 million active accounts, mobile money is entering the mainstream and beco
Benefits of bempedoic acid in hypercholesterolaemia further demonstrated by data presented at the American College of Cardiology’s 69th Annual Scientific Sessions Together with World Congress of Cardiology (ACC.20/WCC)30.3.2020 10:00:00 EEST | Press release
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid and separate results from a Phase 2 study of the bempedoic acid / ezetimibe fixed dose combination (FDC). The data were presented at the American College of Cardiology’s 69th Scientific Sessions Together with World Congress of Cardiology virtual experience (ACC.20/WCC). The 12-week Phase 2 bempedoic acid / ezetimibe FDC study (also known as Study 058) enrolled adult patients with type 2 diabetes mellitus (T2DM) at high risk of cardiovascular disease.6 The bempedoic acid / ezetimibe FDC reduced LDL-C by 40% compared to placebo with no increase in glycated haemoglobin (HbA1c), indicating that glycaemic control was not adversely affected.6 The bempedoic acid / ezetimibe FDC was well tolerated in Study 058, and the incidence of adverse events rates were generally comparable to placebo.6 The first pooled analysis of four Phase 3 clini
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom